...
首页> 外文期刊>BMC Complementary and Alternative Medicine >Antrodia cinnamomea extract inhibits the proliferation of tamoxifen-resistant breast cancer cells through apoptosis and skp2/microRNAs pathway
【24h】

Antrodia cinnamomea extract inhibits the proliferation of tamoxifen-resistant breast cancer cells through apoptosis and skp2/microRNAs pathway

机译:牛樟芝提取物通过细胞凋亡和skp2 / microRNAs途径抑制他莫昔芬耐药性乳腺癌细胞的增殖

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Breast cancer is the most common cancer in women and affects 1.38 million women worldwide per year. Antiestrogens such as tamoxifen, a selective estrogen receptor (ER) modulator, are widely used in clinics to treat ER-positive breast tumors. However, remissions of breast cancer are often followed by resistance to tamoxifen and disease relapse. Despite the increasing understanding of the resistance mechanisms, effective regimens for treating tamoxifen-resistant breast cancer are limited. Antrodia cinnamomea is a traditional medicinal mushroom native only to Taiwan. In this study, we aimed to examine in vitro effect of antrodia cinnamomea in the tamoxifen-resistant cancer. Antrodia cinnamomea was studied for its biological activity against proliferation of tamoxifen-resistant breast cancer by XTT assay. Next, the underlying mechanism was studied by flow cytometry, qPCR and Western’s blotting assay. Our results revealed that the ethanol extract of antrodia cinnamomea (AC) can inhibit the growth of breast cancer cells, including MCF-7 cell and tamoxifen-resistant MCF-7 cell lines. Combination treatment with AC and 10??6?M tamoxifen have the better inhibitory effect on the proliferation of tamoxifen-resistant MCF-7 cells than only AC did. AC can induce apoptosis in these breast cancer cells. Moreover, it can suppress the mRNA expression of skp2 (S-phase kinase-associated protein 2) by increasing the expressions of miR-21-5p, miR-26-5p, and miR-30-5p in MCF-7 and tamoxifen-resistant MCF-7 cells. These results suggest that the ethanol extract of antrodia cinnamomea could be a novel anticancer agent in the armamentarium of tamoxifen-resistant breast cancer management. Moreover, we hope to identify additional pure compounds that could serve as promising anti-breast cancer candidates for further clinical trials.
机译:乳腺癌是女性中最常见的癌症,全世界每年影响138万名女性。抗雌激素药,如他莫昔芬,一种选择性雌激素受体(ER)调节剂,在临床上广泛用于治疗ER阳性的乳腺肿瘤。但是,乳腺癌的缓解通常伴随着对他莫昔芬的抗药性和疾病复发。尽管对耐药机制的认识不断提高,但治疗他莫昔芬耐药乳腺癌的有效方案仍然有限。牛樟芝是一种仅产于台湾的传统药用蘑菇。在这项研究中,我们旨在检查牛樟芝在他莫昔芬耐药癌症中的体外作用。通过XTT分析研究了牛樟芝对他莫昔芬耐药乳腺癌增殖的生物活性。接下来,通过流式细胞仪,qPCR和Western印迹法研究了潜在的机制。我们的结果表明,牛樟芝(AC)的乙醇提取物可以抑制乳腺癌细胞(包括MCF-7细胞和耐他莫昔芬的MCF-7细胞系)的生长。 AC和10 -6 6M他莫昔芬的联合处理对他莫昔芬耐药的MCF-7细胞的增殖具有比仅AC更好的抑制作用。 AC可以诱导这些乳腺癌细胞凋亡。而且,它可以通过增加MCF-7和他莫昔芬-中miR-21-5p,miR-26-5p和miR-30-5p的表达来抑制skp2(S期激酶相关蛋白2)的mRNA表达。耐药的MCF-7细胞。这些结果表明,牛樟芝的乙醇提取物可能是他莫昔芬抗性乳腺癌治疗中的新型抗癌药物。此外,我们希望找出其他可以用作有希望的抗乳腺癌候选药物的纯化合物,以进行进一步的临床试验。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号